Acosta AM, Muñoz MAC, Díaz MLÁ, Zapata DF

Language: Spanish
References: 33
Page: 72-81
PDF size: 246.16 Kb.

ABSTRACT

Background. Recurrence and complications of infectious processes and absenteeism (occupational and scholar) have a direct impact on familial economy; thus, disease-preventive strategies are always better than curing diseases temporally.
Objective. To demonstrate that the ribosomal immunostimulant Ribovac® reduces the number of recurrent respiratory tract infectious episodes, the consumption of antibiotics and other drugs and the scholar and parental absenteeism.
Material and methods. A prospective, longitudinal, descriptive and observational study including 208 pediatric patients was carried out. Subjects, who were older than five months, with a high or potential risk of recurrence of acute respiratory diseases, were chosen from the outpatient clinic of pediatrics from the Hospital de Pensiones Civiles of the Chihuahua State, who attended from May 15^th, 2000 to March 31^st, 2001.
Results. Two hundred eight patients were studied; age ranged from six months to seven years old. Eighty-two percent of subjects (n= 170) had suffered from four infectious episodes during the previous six month period. During treatment period only 74% of patients (n= 153) had one to three episodes of respiratory infection. All patients had fever concomitant to the infectious episode, in 65% (n= 135) it lasts more than three days. After treatment 59% of patients (n= 122) did not have fever and in the remaining 41% (n= 86) it lasts one to two days. Length of previous-to-study antimicrobial treatment was of 8-10 days in 35% of cases (n= 73) and of five to seven days in 65% (n= 135). During treatment phase, length scheme was reduced to 7% for the former and 58% for the latter.
Conclusions. It is confirmed that this immuno-stimulant agent is an efficacious resource in the prevention of respiratory bacterial illnesses in children and adults, because they reduce infection recurrence, avoid chronicity, shortens the convalescence period and reduce the intensity of infections. Cost-benefit of prevention reduces not only costs in antimicrobial agents, but also days of scholar and occupational absenteeism.

REFERENCES

1. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 1991; 58: 150-54.

2. Vautel JM, Cauquil J, Perruchet AM, Thomas AM. Prevention of recurrent ear, nose, and throat infections in young children with Ribomunyl®: double-blind placebo-controlled study. Curr Ther Res 1993; 53: 722-29.

3. Collet JP, Ducruet T, Kramer MS, et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending daycare centers. Pediatr Infect Dis J 1993; 12: 648-52.

4. Quezada A, Maggi L, Pérez MA, Rodríguez J. Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinemia. J Invest Allergol Clin Immunol 1999; 9: 225-29.

5. Rodríguez OAR. Amoxiclav-Ribovac vs Ribovac-inmunoglobulina en niños con infección respiratoria alta recurrente. Alergia, Asma e Inmunología Pediátricas 2001; 10(3): 104-18.

6. Quezada LA. Uso de inmunoestimulantes en pediatría. Rev Chil Pediatr 1999; 70(3): 123-29.

7. Kim PE, Musher DM, Glezen WP, Rodríguez-Barradas MC, Nahm WK, Wright CE. Association of invasive penumococcal disease with season, atmospheric conditions, air pollution and the isolation of respiratory viruses. Clin Infect Dis 1996; 22: 100-6.

8. Quiambao BP, Gatchalian SR, Halonen P, Lucero M, Sombrero L, Paladin FJ, et al. Coinfection is common in measles-associated pneumonia. Pediatr Infect Dis J 1998; 17: 89-93.

9. Sonoda S, Gotoh Y, Bann F, Nakayama T. Acute lower respiratory infections in hospitalized children over a 6 years period in Tokio. Pediatric Int 1999; 41: 519-24.

10. Parrott RH, Vargosko AJ, Kim HW, Chanock RM. Clinical syndromes among children. Am Rev Respir Dis 1963; 88: 73-88.

11. Videla C, Carballal G, Misirlian A, Aguilar M. Acute lower respiratory infections due to respiratory syncitial virus and adenovirus among hospitalized children from Argentina. Clin Diagn Virol 1998; 10: 17-23.

12. Boyle P, Bellanti JA, Robertson C. Metaanálisis de estudios clínicos publicados sobre una vacuna ribosómica (Ribomunyl) en la prevención de las infecciones respiratorias. Biodrugs 2000 Dec; 14(6): 389-408.

13. Castañeda JL, Chávez R. Estudio de eficacia de un tratamiento preventivo de 3 meses de duración con derivados ribosomales en niños con infección respiratoria recurrente que asisten a guardería. Rev. Enf Inf Ped 2002 Abr-Jun; 15(60): 121-26.

14. Youmans A. & Youmans G. Immunogenic Activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. Journal of bacteriology 1965 May; 89(5): 1291-98.

15. Roques C. Frayret MN, Luc J. et al. Effect of an in vivo immunostimulant treatment on PMN functions interaction with antibiotics in vitro. Int J. immunopharmacol 1991; 13: 1051-57.

16. Roques C, Frayret MN, Luc J, et al. In vitro stimulation of polymorphomuclear cell adhesion by Ribomunyl and antibiotic + Ribomunyl combinations; eccects on CD 18, CD 35 and CD 16 expression. Int J Immunopharmacol 1993; 15: 163-73.

17. Zanin C, Perrin P, Perruchet AM, et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharmacol 1994; 16: 497-505.

18. Nascimento J, Drugs. Recurrent respiratory tract infections in paediatric patients. Suppl 54 1997; 1: 44.

19. Menardo JL, Perruchet AM. Epidemiologic and therapeutic survey: prevention of respiratory infections among children with respiratory allergy. Eur Respir J 1990; 10: 385s-386s.

20. Mora R, et al. Efficacy and tolerability of immucytal in the prevention and treatment of respiratory tract infectios in adults: a randomizex, placebocontrolled, double blind study. Int J Immunotherapy 2001; XVII(1): 31-40.

21. Leophonte. Prevention of bronchial superinfections in chronic bronchitic patients with Ribomunyl tablets. Congrès de Pneumonologie de lange Française. Algiers 1989.

22. Kolopp-Sarda MN, Bené MC, Allaire JM, et al. Kinetics of specific IgA secretory response in human saliva after oral challenge by a ribosomal immunostimulant. Int J Immunopharmacol 1997; 19(3): 181-86.

23. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention of upper and lower respiratory tract infections in

24. Banz K, Schwicker D, Thomas AM. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmaco Economics 1994; 6: 464-7761.

25. Centanni, et al. Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. Journ of Chemother 1997; 9(4): 273-78.

26. Bocaccio C, et al. Identification of a clinical-grade maturation factor for dendritic cells. J Immunother 2002; 25(1): 88-96.

27. Bystrom, et al. Comparison of influence of ribosomal immunotherapy on plasmatic level of total IgE and cytokines IL 5 IL 4 1L 12 and IFNg in atopic and non atopic adults during grass pollen season. Abstr no.1080.

28. Garabedian EN, Dubreuil C, Triglia JC. Efectiveness and tolerance of Ribomunyl tablets in preventing middle ear infections in children affected by S.O.M. Intl Cong on prev. of Infec 1990, June, Nice, France.

29. Fauré GC, Bené MC Simon C, et al. Increase in specific antibodyforming cells in humkan tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharmacol. 1990; 12(3): 315-20.

30. Herrero T, et al. Ribomunyl in the treatment of otitis media with efusión. Ribosomal Immutherapy Symposium. Annecy France, September 2004.

31. Giovannini M. et al. Immucytal in the preventiona and treatment of recurrent upper respiratory tract infections in children a randomised, placebocontrolled, double-blind study. Int J. of immunotherapy 2000; XVI(3/4): 67-75.

32. Galioto G.B, Galioto P, et al. Efficacy and tolerability of Immucytal in the prevention and treatment of the respiratory tract infections in adults: a randomised, placebo-controlled, double-blind study. Int J. of immunotherapy 2001; XVII(1); 31-40.

33. Gramiccioni E. Efficacy and tolerability of Immucytal in the prevention of the respiratory tract infections: a randomised, placebo-controlled, double-blind study.